Tofacitinib Synthesis – An Asymmetric Challenge | Zendy

Carvalho Luísa C. R. | Zendy; Lourenço Ana | Zendy; Ferreira Luísa Maria | Zendy; Branco Paula Sério | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Tofacitinib Synthesis – An Asymmetric Challenge

Author(s) -

Carvalho Luísa C. R.,

Lourenço Ana,

Ferreira Luísa Maria,

Branco Paula Sério

Publication year - 2019

Publication title -

european journal of organic chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 155

eISSN - 1099-0690

pISSN - 1434-193X

DOI - 10.1002/ejoc.201801180

Subject(s) - tofacitinib , chemistry , janus kinase , rheumatoid arthritis , psoriatic arthritis , piperidine , active ingredient , chirality (physics) , combinatorial chemistry , pharmacology , stereochemistry , janus kinase inhibitor , arthritis , kinase , medicine , biochemistry , nambu–jona lasinio model , physics , quantum mechanics , quark , chiral symmetry breaking

Tofacitinib is a Janus activated kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis and active psoriatic arthritis. Its synthesis normally involves long synthetic sequences due to the chirality associated to the piperidine ring. This review is a comprehensive analysis of the different synthetic methods used to prepare this active pharmaceutical ingredient (API), covering the related journal and patent literature.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research